Telomir Pharmaceuticals, Inc. (TELO) Financial Statements
Industry: Pharmaceutical Preparations
Net income was -$10.4M, or -$0.33 per diluted share. Operating activities generated -$3.7M of cash, leaving -$3.7M of free cash flow. At fiscal year end, Telomir Pharmaceuticals held $7.3M in total assets against $1.4M in total liabilities.
Open the full interactive Telomir Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Telomir Pharmaceuticals Key Stats
| Share Price | $1.09 |
|---|---|
| Market Cap | $66.3M |
| 52-Week Range | $0.92 – $1.73 |
| Shares Outstanding | 60.8 million (basic, 2026 Q2) |
Telomir Pharmaceuticals Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Pre-Tax Income | -$13.1M | -$16.5M | -$10.4M |
| Net Income | -$13.1M | -$16.5M | -$10.4M |
| Diluted EPS | -$0.45 | $0.56 | -$0.33 |
Telomir Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Net Income | -$1.1M | -$2.1M | -$990,947 | -$1.7M |
| Diluted EPS | -$0.03 | -$0.07 | -$0.03 | -$0.79 |
Telomir Pharmaceuticals Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Current Assets | $435,225 | $1.3M | $7.3M |
| Total Assets | $4.8M | $1.3M | $7.3M |
| Current Liabilities | $1.3M | $680,968 | $1.4M |
| Total Liabilities | $1.3M | $680,968 | $1.4M |
| Shareholders' Equity | $3.4M | $600,000 | $5.9M |
Telomir Pharmaceuticals Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$3.9M | -$5.1M | -$3.7M |
| Cash From Financing | $3.9M | $6.3M | $9.7M |
| Free Cash Flow | -$3.9M | -$5.1M | -$3.7M |
Figures from Telomir Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Telomir Pharmaceuticals financials page for every line item.
Telomir Pharmaceuticals Company Profile
| Ticker | TELO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Miami, Florida |
| Incorporated in | Florida |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001971532 |
Frequently Asked Questions
What was Telomir Pharmaceuticals' net income in fiscal 2025?
Telomir Pharmaceuticals reported net income of -$10.4M for fiscal 2025.
What was Telomir Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Telomir Pharmaceuticals' diluted EPS was -$0.33 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Telomir Pharmaceuticals generate in fiscal 2025?
Telomir Pharmaceuticals generated -$3.7M of free cash flow in fiscal 2025.
How many shares of Telomir Pharmaceuticals are outstanding?
Telomir Pharmaceuticals reported a weighted average of 60.8 million basic shares outstanding in 2026 Q2.
What is Telomir Pharmaceuticals' market cap?
Based on its latest closing price, Telomir Pharmaceuticals (TELO) has a market capitalization of about $66.3M.
When does Telomir Pharmaceuticals' fiscal year end?
Telomir Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Telomir Pharmaceuticals headquartered?
Telomir Pharmaceuticals lists its business address in Miami, Florida in its SEC filings.